Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757347 | 0.83 | — | — | |
| SCHEMBL2210649 | 0.82 | HMGCR (0.35) | HMGCRHSP90AB1L3MBTL1 | |
| SCHEMBL6762156 | 0.81 | — | — | |
| SCHEMBL6762153 | 0.81 | — | — | |
| SCHEMBL6760856 | 0.81 | — | — | |
| SCHEMBL6760859 | 0.81 | — | — | |
| SCHEMBL6762080 | 0.81 | HMGCR (0.33) | HMGCR | |
| SCHEMBL6762123 | 0.76 | — | — | |
| SCHEMBL614127 | 0.61 | PDE4A (0.31) | — | |
| SCHEMBL6760776 | 0.61 | HSD17B10 (0.32) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723853-B2 | ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH | 2004-04-20 | — | — | US | disclosed |
| US-20030073840-A1 | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073840-A1 | Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins | FOLR1, POR, FOLR2 | HMGCR 260/4885HSP90AB1 2621/4885L3MBTL1 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.